ATE231549T1 - Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung - Google Patents

Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Info

Publication number
ATE231549T1
ATE231549T1 AT97933740T AT97933740T ATE231549T1 AT E231549 T1 ATE231549 T1 AT E231549T1 AT 97933740 T AT97933740 T AT 97933740T AT 97933740 T AT97933740 T AT 97933740T AT E231549 T1 ATE231549 T1 AT E231549T1
Authority
AT
Austria
Prior art keywords
viruses
viral
recombining
aqueous suspension
medical use
Prior art date
Application number
AT97933740T
Other languages
German (de)
English (en)
Inventor
Claude Sene
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE231549T1 publication Critical patent/ATE231549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT97933740T 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung ATE231549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (1)

Publication Number Publication Date
ATE231549T1 true ATE231549T1 (de) 2003-02-15

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933740T ATE231549T1 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US6451256B1 (OSRAM)
EP (1) EP0853660B1 (OSRAM)
JP (1) JP3681401B2 (OSRAM)
AT (1) ATE231549T1 (OSRAM)
AU (1) AU711409B2 (OSRAM)
CA (1) CA2232604C (OSRAM)
DE (1) DE69718612T2 (OSRAM)
DK (1) DK0853660T3 (OSRAM)
ES (1) ES2187798T3 (OSRAM)
FR (1) FR2751343B1 (OSRAM)
WO (1) WO1998002522A1 (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
WO2000032233A2 (en) * 1998-12-03 2000-06-08 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
HK1045716A1 (zh) * 1999-04-09 2002-12-06 阿文蒂斯药物股份有限公司 用於保存感染性重組腺病毒的組合物
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001066137A1 (en) * 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
US20040101964A1 (en) * 2000-05-10 2004-05-27 Shigemitsu Takashima Method of preparing virus vector
EP1453537A1 (en) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
PL371261A1 (en) * 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
CA2555412C (en) * 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
ES2578514T3 (es) 2010-02-15 2016-07-27 Crucell Holland B.V. Método para la producción de vectores adenovíricos
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EP2646051A4 (en) 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
SG190419A1 (en) 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations
ES2582504T3 (es) 2012-03-12 2016-09-13 Crucell Holland B.V. Lotes de adenovirus recombinantes con extremos alterados
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
BR112016015936A2 (pt) 2014-01-09 2017-09-19 Transgene Sa Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
MY190320A (en) 2016-04-05 2022-04-13 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EP3455358B1 (en) 2016-05-12 2020-08-26 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR CANCER THERAPY
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
MA71423A (fr) 2020-03-19 2025-04-30 Trizell Ltd. Système de stockage de virus sensible à la température
JP2023533584A (ja) 2020-07-13 2023-08-03 トランジェーヌ 免疫低下の処置
JP2024504875A (ja) 2021-02-01 2024-02-01 ▲い▼尊生物医薬（浙江）有限公司 標的タンパク質分解システムおよびその応用
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
KR20250034101A (ko) 2022-07-01 2025-03-10 트랜스진 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
JP2025528219A (ja) 2022-08-18 2025-08-26 トランジェーヌ キメラポックスウイルス

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
AU3698697A (en) 1998-02-09
DK0853660T3 (da) 2003-05-05
US6451256B1 (en) 2002-09-17
CA2232604A1 (fr) 1998-01-22
FR2751343A1 (fr) 1998-01-23
AU711409B2 (en) 1999-10-14
ES2187798T3 (es) 2003-06-16
US20030082206A1 (en) 2003-05-01
EP0853660B1 (fr) 2003-01-22
JP2000500026A (ja) 2000-01-11
JP3681401B2 (ja) 2005-08-10
EP0853660A1 (fr) 1998-07-22
CA2232604C (fr) 2005-06-28
DE69718612D1 (de) 2003-02-27
DE69718612T2 (de) 2003-11-06
FR2751343B1 (fr) 1998-12-18
WO1998002522A1 (fr) 1998-01-22

Similar Documents

Publication Publication Date Title
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
DE69635871D1 (de) Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
ATE292177T1 (de) Gentherapy von lungenkrankheiten
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
ATE275984T1 (de) Biokompatible kolloide mit geringer zelladhäsion und aktiver stabilisierung von blutproteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853660

Country of ref document: EP